Using AI+ experimental robots to drive new drug research and development, Jingtai Technology and Eli Lilly carry out new drug discovery cooperation

Recently, Jingtai Technology, which uses AI experimental robots to drive drug research and development, announced that it has signed an AI small molecule new drug discovery cooperation agreement with Eli Lilly, a well-known American pharmaceutical company. The total revenue from advance payments and milestones can reach US$250 million. . This cooperation will give full play to the technical advantages of combining the "dry laboratory" of Jingtai Technology's AI drug research and development platform and the "wet laboratory" of automated robots to design and deliver competitive candidate compounds from scratch for Lilly, empowering Lilly to develop And promote the competitive new drug pipeline to clinical practice.

According to the terms of the agreement, Lilly will pay an upfront payment and milestone fees of up to US$250 million for an undisclosed innovative target to be developed by Innotech using its unique small molecule drug discovery platform ID4Inno™. First-of-its-kind innovative drugs to fill unmet clinical drug needs. As the pioneer of AI experimental robots, Jingtai Technology will continue its trinity drug research and development model of "expert experience in intelligent algorithm robot experiments" and work closely with the Eli Lilly team to complete one-stop de novo discovery of new drugs and deliver the drug candidates to Eli Lilly. Preclinical development, clinical development and subsequent commercialization.

According to Jingtai Technology, ID4Inno™ is equipped with Jingtai Technology’s high-precision computational chemistry algorithms and more than 500 AI models. It can explore an ultra-large-scale druggable space for targets and design and screen a variety of drug properties. . The molecules with the highest comprehensive scores will be synthesized in an automated laboratory composed of hundreds of robot workstations, and their activity and druggability will be verified through a series of biochemical, cellular, pharmacological and pharmacological tests, and the computational data and experimental data will Rapid feedback is given to the ID4Inno™ algorithm platform to form a closed loop of DMTA (Design-Intelligent Manufacturing-Testing-Analysis) between AI algorithms and real experiments, and the molecular design is continuously optimized during model iteration until an ideal drug is found with all aspects of its patented drug properties exceeding predetermined benchmarks. candidate molecules. Jingtai Technology's AI cryo-electron microscopy platform, in vitro and in vivo screening and evaluation platform and other technologies will also play a role in this cooperation to accelerate Jingtai's design and delivery of active molecules with innovative skeletons.

As a representative company of AI pharmaceuticals in Pudong, Jingtai Technology is positioned as a biomedicine and new material research and development platform, providing pharmaceutical companies with one-stop small molecule drug discovery, biopharmaceutical innovation discovery, automated chemical services and pharmaceutical solid state Research services, with more than 200 pharmaceutical companies and scientific research institution customers around the world. Its AI robot intelligent research and development platform integrates a series of cutting-edge intelligent algorithm tools from quantum physics, computational chemistry and AI. At the same time, its independently developed automated laboratory uses efficient parallel robot experiments to free human scientists from complex experimental trial and error. Liberated.

This "virtual and real" R&D platform can quickly and large-scale generate high-quality data from the real world, further improving Jingtai Technology's ability to predict and verify drug candidates, and empowering experts to innovate and explore more efficiently. Achieve breakthroughs. Jingtai Technology has built thousands of square meters of automated experimental workstation clusters in Shenzhen and Shanghai, and plans to replicate this mature technology in many places to provide strong delivery guarantee for ongoing new drug discovery cooperation on dozens of platforms.

Dr. Ma Jian, co-founder and CEO of Jingtai Technology, said, "Jingtai Technology has opened up the data closed loop of intelligent algorithms and robot experiments, and has unique technical advantages and rich successful experience in challenging new targets. We expect Our platform can help Lilly achieve more profitable pipeline development to bring high-quality and efficient drugs to patients around the world as early as possible."

Source: Pudong Release

The above is the detailed content of Using AI+ experimental robots to drive new drug research and development, Jingtai Technology and Eli Lilly carry out new drug discovery cooperation. For more information, please follow other related articles on the PHP Chinese website!